Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy

Kopp, Matthias; Hamelmann, Eckard; Bendiks, Meike; Zielen, Stefan; Kamin, Wolfgang; Bergmann, Karl‐Christian; Klein, Christian; Wahn, Ulrich

doi:10.1111/pai.12098

Cited by 67 publications

(60 citation statements)

References 16 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A multicenter placebo-controlled randomized trial evaluating omalizumab or placebo in 140 subjects as an added therapy to SCIT over 2 years for the treatment of seasonal AR during the pollen season demonstrated that the concomitant use of omalizumab reduced symptom severity by 39% over SCIT alone and also improved asthma control and asthma and AR quality of life [145]. A subsequent study by the same group failed to demonstrate sustained effects of omalizumab throughout the remaining duration of SCIT for pollen allergy [146]. Preliminary data for the use of omalizumab as adjunct therapy to treat cow milk allergy and bee venom allergy have shown some encouraging results but larger well-designed studies have not been conducted to date.…”

Section: Adjunct Therapy Omalizumabmentioning

confidence: 93%

Current developments for improving efficacy of allergy vaccines

Sandrini

Rolland

O’Hehir

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

Allergic diseases are prevalent worldwide. Allergen immunotherapy (AIT) is a current treatment for allergy, leading to modification of the natural course of disease. Mechanisms of efficacy include Treg through release of IL-10 and TGF-β and specific IgG4 blocking antibodies. Subcutaneous and sublingual routes are popular, but uptake is limited by inconvenience and safety concerns. Inclusion criteria limit application to a small proportion of allergic patients. New forms of immunotherapy are being investigated for more efficacious, convenient and safer options with promising advances in recent years. The rationale of reducing vaccine allergenicity to increase safety while improving immunogenicity led to investigation of T-cell epitope-based peptides and recombinant allergen derivatives. Additionally, different routes of administration and adjuvants and adjunct therapies are being explored. This review discusses the current status of AIT and recent advances to improve clinical efficacy, safety and long-term immune tolerance.

show abstract

Section: Adjunct Therapy Omalizumabmentioning

confidence: 93%

Current developments for improving efficacy of allergy vaccines

Sandrini

Rolland

O’Hehir

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…45 Omalizumab therapy also improved the symptom relief seen with SCIT, but this improvement did not continue after the omalizumab was discontinued. [45][46][47] These studies have not addressed the optimal pretreatment time for omalizumab to impart added safety to SCIT. A reasonable pretreatment based J ALLERGY CLIN IMMUNOL PRACT VOLUME -, NUMBERon the data to date suggests an 8-to 12-week course of omalizumab before allergen immunotherapy.…”

Section: Immunotherapymentioning

confidence: 97%

The Use of Anti-IgE Therapy Beyond Allergic Asthma

Stokes

Casale

2015

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

“…Clinical evidence also suggests that it ameliorates other allergic co-morbidities such as food allergy, eczema and rhinoconjunctivitis. Treatment with Omalizumab could also be used to protect against anaphylaxis during start-up of immunotherapy in severely allergic children [98,99].…”

Section: Omalizumabmentioning

confidence: 99%

Update on the current methods for the diagnosis and treatment of severe childhood asthma

Konradsen

Osvald

Hedlin

2015

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

The level of asthma control is the key outcome towards which asthma management is evaluated. The majority of children with asthma can obtain adequate control of symptoms through avoidance of triggering factors and/or with the help of low to moderate doses of current available medications. However, there is still a group of children with poor symptom control despite intensive treatment. The current review will provide an overview of a standardized approach to characterize this heterogeneous group of severely sick children. Factors that attenuate the effect of the prescribed treatment and make asthma difficult to treat are discussed. In addition, the usefulness of current methods of assessing asthma severity, pulmonary function, allergy and airway inflammation is also described. Finally, an overview of therapeutic options for children with severe asthma is provided.

show abstract

Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy

Cited by 67 publications

References 16 publications

Current developments for improving efficacy of allergy vaccines

Current developments for improving efficacy of allergy vaccines

The Use of Anti-IgE Therapy Beyond Allergic Asthma

Update on the current methods for the diagnosis and treatment of severe childhood asthma

Contact Info

Product

Resources

About